A Look into Clinical Chemistry Analyzers Industry……Deep Analysis…..
The global clinical
chemistry analyzers market
size is expected to reach USD 16.0
billion by 2025, according to a new study by Grand View Research, Inc. The
growing prevalence of chronic diseases is anticipated to be responsible for the
high urgency to adopt clinical chemistry analyzers, which thereby widens the
scope for growth during the forecast period. In addition, growing base of
geriatric and bariatric population, which is highly susceptible to chronic
diseases, is presumed to impel the demand further. Consequently, the resultant
high sample volume requiring high capability analyzing devices is driving the
market growth.
With Covid-19 infections rising globally, the
apprehension regarding a shortage of essential life-saving devices and other
essential medical supplies in order to prevent the spread of this pandemic and
provide optimum care to the infected also widens. In addition, till a
pharmacological treatment is developed, ventilators act as a vital treatment
preference for the COVID-19 patients, who may require critical care. Moreover, there
is an urgent need for a rapid acceleration in the manufacturing process for a
wide range of test-kits (antibody tests, self-administered, and others). The
report will account for Covid19 as a key market contributor.
Moreover, increasing awareness pertaining
to benefits associated with these devices is also a high impact rendering
driver for clinical chemistry analyzers market. Advent of advanced chemistry
analyzers has resulted in improved point-of-care testing capabilities, and thus
created high potential growth opportunities for the market. In addition,
technological advancements in preanalytical, analytical, and post analytical
stages due to analyzing devices & reagents improved their diagnostic
capabilities and overall efficiency, which is predicted to propel the growth
further. These advancements include advent of microchips, sensors,
chemometrics, and robotics. Furthermore, consistent efforts by public as well
private healthcare organizations to increase the reliability of data have
rapidly engendered the integration of automated chemistry analyzers and
immunoassay systems, thereby resulting in overall reduction of workload in
laboratories, thus propelling the demand.
To Request Sample Copy of this report, click the link:
Further Key Findings From the Study Suggest:
·
Reagents held a substantial
share in product segment in 2015. The substantial share can be attributed to increasing
reagent rental agreements and availability resulting in quick global access
·
Lipid panel is anticipated to
exhibit lucrative CAGR during the forecast period owing to increasing adoption,
as the demand for screening tests for cholesterol and triglyceride levels in
case of cardiovascular disorders and diabetes has increased
·
In 2016, North America
accounted for substantial share in the global clinical chemistry analyzers
market, as a consequence of local presence of prominent companies involved in
high R&D investments
·
Asia Pacific is anticipated to
grow at an exponential CAGR due to unmet patient needs, continuous
technological & infrastructural upgradation, and growing healthcare
expenditure
·
Some key participants such as
Mindray Medical International Ltd.; Johnson & Johnson; and F.Hoffmann-La
Roche Ltd. are undertaking various sustainability strategies, such as new
product development & frequent product approvals, to gain competitive
advantage
·
For instance, in August 2016,
Mindray announced the premarket FDA clearance for Mindray BA-800M clinical
chemistry analyzer allowing it to distribute its product
The
global clinical chemistry analyzers market accounted for USD 9.9 billion in
2016 and is expected to grow at a CAGR of 5.5% during the forecast period. The
increasing prevalence of chronic diseases, such as diabetes, is predicted to be
one of the high impact rendering drivers of this market. This subsequent
increase in disease prevalence has triggered companies to produce advanced analyzers
at a large scale, to aid in diagnosis. Consequently, the high need for
chemistry analyzers led to an unprecedented growth in new market entrants,
resulting in high competition.
The
technological innovations in clinical chemistry analyzers have led to early
disease detection and specialized diagnosis in the areas of oncology,
gynecology, & endocrinology and enabled testing on a larger scale. The
advancements comprise advanced modeling & parameter estimation, better
resolution, improved pattern recognition, computer-assisted interpretation, and
artificial intelligence.
The benefits of abovementioned
advancements and automated analyzers are automatic data acquisition, greater
process control allowing real-time automation, efficient parameter monitoring,
and automatic variable adjustment. These tools also offer analysis of wide
range of samples and facilitate immediate generation of results, reflecting
their potential applications in intensive care unit, outpatient clinics, and
emergency as well as surgical wards in future. These benefits are estimated to
drive physician preference for these analyzers, thus creating high potential
opportunities for growth during the forecast period.
Have any Query? Ask our Experts:
Reagents
accounted for the largest share in the product segment in 2015. The substantial
share is predicted to be a consequence of wide array of reagents present in the
market, catering to different requirements of clinicians. These reagents
predominantly include enzymes, substrates, specific proteins, electrolytes,
lipids and others, which are imperative to obtain accurate results in
analytical procedures.
In
addition, reagents are believed to be highly cost efficient, possess optimum
sensitivity, linearity, and precision, which thereby, ensures minimized
performance variation. The aforementioned benefits are predicted to be highly
responsible for encouraging clinicians to use reagents for accurate diagnosis.
Grand View Research has segmented the
global clinical chemistry analyzers market on the basis of product, test, end
use, and region:
Clinical Chemistry Analyzers Product Outlook (Revenue,
USD Million, 2014 - 2025)
·
Analyzers
o Small
o Medium
o Large
o Others
·
Reagents
o Calibrators
o Controls
o Standards
o Others
·
Others
Clinical Chemistry Analyzers Test Outlook (Revenue, USD
Million, 2014 - 2025)
·
Basic Metabolic Panel(BMP)
·
Electrolyte Panel
·
Liver Panel
·
Lipid Profile
·
Renal Profile
·
Thyroid Function Panel
·
Specialty Chemical Tests
Clinical Chemistry Analyzers End-Use Outlook (Revenue,
USD Million, 2014 - 2025)
·
Hospitals
·
Academic Research Centers
·
Diagnostic Laboratories
·
Others
About Grand View Research
Grand View Research, Inc. is a U.S.
based market research and consulting company, registered in the State of California
and headquartered in San Francisco. The company provides syndicated research
reports, customized research reports, and consulting services. To help clients
make informed business decisions, we offer market intelligence studies ensuring
relevant and fact-based research across a range of industries, from technology
to chemicals, materials and healthcare.

Comments
Post a Comment